Navigation Links
Patient Safety Technologies, Inc. Closes $7.1 Million Common Stock Offering
Date:3/31/2011

IRVINE, Calif., March 31, 2011 /PRNewswire/ -- Patient Safety Technologies, Inc. (the "Company") (OTC Bulletin Board: PSTX) today announced the closing of a $7.1 million common stock financing.  The investors, led by a new institutional investor, together with several existing shareholders and certain members of senior management, purchased 9.48 million shares of common stock at a price of $0.75 per share.  Proceeds from the offering will be used for general corporate purposes including investing in the continued market penetration of the Company's core offering, the SurgiCount Safety-Sponge® System, a solution proven to improve patient outcomes and reduce healthcare costs by preventing one of the most common errors in surgery, retained surgical sponges.

"After successfully implementing an aggressive cost reduction and restructuring initiative last year, the subsequent goal of this new management team was to properly capitalize the company to help us achieve our growth objectives.  This offering will help us continue to execute our growth plans and positions us well to accelerate our market expansion and new product development," said Brian E. Stewart, President and Chief Executive Officer of Patient Safety Technologies.

Given the substantial improvement to the Company's liquidity from this offering and the proximity of the offering to the normal due date of Company's annual report on Form 10K for the fiscal year ended December 31, 2010, the Company also announced today that it intends to file a Form 12B-25 to allow the Company additional time to evaluate the impact of the offering on its financial position.  The Company expects that it will comply with SEC's Rule 12B-25 and accordingly that it will be deemed timely in the filing of its Form 10K.

About Patient Safety Technologies, Inc. and SurgiCount Medical

Patient Safety
'/>"/>

SOURCE Patient Safety Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction
2. Promidian Survey Finds Growing Support for Patient-Centered Medical Home
3. Newtech, Inc., a Leading Chinese EMS Patient Monitoring Company, Partners With Masimo to Incorporate rainbow® SET Noninvasive Measurement Capabilities Into New Patient Monitors
4. Detroit Medical Center Becomes First in Southeast Michigan to Study an Implantable Device, Designed to Reduce Patient Time to the ER and Improve Survival Rates From Heart Attack in High-Risk Patients
5. Torrance Dentist, Dr. Robert Mondavi, Now Uses Digital X-Rays for Comfort and Safety of the Patients
6. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
7. New Studies Show Clinical Advantages of Masimo Noninvasive Hemoglobin, PVI, and Perfusion Index in Critically-ill Patients
8. Gateway to Hope: Missouri Nonprofit Leads the Fight against Breast Cancer by Providing Donated Medical and Surgical Care at No Cost to Patients
9. Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeichs Genous™ Stent in Diabetic Patients
10. GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients
11. National Nasal Allergy Survey Reveals Unmet Needs Still Exist Among Patients Living With Allergic Rhinitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/22/2014)... influenced by low exposure to testosterone in the womb, ... men,s testosterone levels may be determined before they are ... the hormone than others is important because testosterone is ... hormone have been linked to obesity, diabetes and heart ... for producing testosterone in adults known as Leydig ...
(Date:4/22/2014)... fiction: In enemy territory, activate your cloaking device. And ... to the immune system. Now scientists at Harvard,s Wyss ... tactics to build the first DNA nanodevices that survive ... the way for smart DNA nanorobots that could use ... doctors can today; target drugs to tumors, or even ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Toronto say a sleep disorder that ... best current predictor of brain diseases like Parkinson,s and ... not just a precursor but also a critical warning ... says associate professor and lead author Dr. John Peever. ... cent of people with RBD will develop a brain ...
(Date:4/21/2014)... Minn. Acute respiratory distress syndrome is a ... who develop the lung disorder postoperatively are at ... those who survive the syndrome may still bear ... Mayo Clinic-led study is helping physicians better identify ... preventing this dangerous and costly surgical complication. ...
Breaking Medicine News(10 mins):Health News:Cloaked DNA nanodevices survive pilot mission 2Health News:Cloaked DNA nanodevices survive pilot mission 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Acute respiratory distress syndrome: Study IDs surgical patients at risk 2
... New York, NY (June 6, 2012) A clinical ... molecular therapy called vismodegib (trade name Erivedge), can dramatically ... of new ones, in patients with basal cell nevus ... sometimes hundreds or thousands, of skin cancers on each ...
... In a Phase 2 study presented at the ... Oncology (ASCO), clinical researchers from University Hospitals Case Medical ... to treat gynecologic cancers, shortening radiation treatment time from ... stereotactic body radiotherapy (SBRT), has been used on other ...
... THURSDAY, May 31 (HealthDay News) -- Live chicks and ducklings ... a salmonella outbreak that had sickened 93 people in 23 ... in an update Thursday. Eighteen people have been ... under investigation. Among the reported cases so far, illnesses surfaced ...
... , THURSDAY, May 31 (HealthDay News) -- Meat, ... associated with a fivefold increased risk of immediate gout flare-ups, ... arthritis that often first occurs in the big toe. Anecdotal ... but it hasn,t been clear whether they cause immediate attacks. ...
... , THURSDAY, May 31 (HealthDay News) -- More than ... new government report shows. "Untreated tooth decay is ... Dye, an epidemiologist at the U.S. Centers for Disease ... appears that we haven,t been able to make any ...
... Steven Reinberg HealthDay Reporter , THURSDAY, May 31 ... the United States may be infected with chronic hepatitis B ... come from countries in Asia and Africa, where regular vaccination ... "Hepatitis B is a common infection transmitted at birth or ...
Cached Medicine News:Health News:New drug found effective against rare form of basal cell skin cancer 2Health News:New drug found effective against rare form of basal cell skin cancer 3Health News:University Hospitals Case Medical Center experts present at ASCO Annual Meeting 2Health News:University Hospitals Case Medical Center experts present at ASCO Annual Meeting 3Health News:Ohio Mail-Order Hatchery Now Linked to Salmonella in 23 States 2Health News:Gout Flare-ups Rise Sharply With Certain Foods: Study 2Health News:1 in 5 Americans Has Untreated Cavities: CDC 2Health News:Hepatitis B Infection Rates in U.S. Higher Than Thought 2Health News:Hepatitis B Infection Rates in U.S. Higher Than Thought 3
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
... a visually read, qualitative immunochromatographic method for ... a bacterium that grows in the stomach ... and some gastric cancers. FlexSure HP, available ... serum samples, provides the physician with the ...
Medicine Products: